Search
Cancer Paid Clinical Trials in Massachusetts
A listing of 532 Cancer clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
433 - 444 of 532
The state of Massachusetts currently has 532 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer
Recruiting
This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/26/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Gastric Cancer
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Recruiting
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Dana-Farber Cancer Insitute, Boston, Massachusetts +4 locations
Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Recruiting
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
Recruiting
This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer.
The names of the study treatment involved in this study are:
* Dostarlimab
* Niraparib
* Radiation Therapy (RT), which is given per standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Breast Cancer, Triple Negative Breast Cancer
Abemaciclib and Endocrine Therapy in Older Patients with Breast Cancer.
Recruiting
This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
09/17/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
YES Study - Newly Diagnosed/Metastatic Intervention
Recruiting
This research study is being done to monitor common symptoms and behavior, and to provide supportive care information and peer support, as well as research opportunities for young women ages of 18-39 years old who have been diagnosed with stage 0-IV stage breast cancer using a web-based portal (YES), built for smartphones, tablets, and computers.
Gender:
FEMALE
Ages:
Between 18 years and 39 years
Trial Updated:
09/09/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Symptom, Behavioral
Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer
Recruiting
This prospective, multicenter, 1:1 randomized, controlled trial is designed to evaluate the safety and effectiveness of the Breast Cancer Locator (BCL) in subjects with non-palpable invasive breast cancer or ductal carcinoma in situ (DCIS). Subjects will be randomized to breast conserving surgery (BCS) utilizing either the BCL or wire localization (WL) to guide surgery.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/04/2024
Locations: Tufts Medical Center, Boston, Massachusetts +2 locations
Conditions: Breast Cancer Female
A Phase I Intravesical PPM Therapy for NMIBC
Recruiting
This clinical trial is to determine the safety and effectiveness of an investigational bladder cancer drug named "PLZ4-coated paclitaxel-loaded nanoscale micelle (PPM)." PPM is tiny particles that contain the chemotherapy drug paclitaxel. PLZ4 is a molecule that can possibly guide PPM to specifically target and deliver paclitaxel into and kill bladder cancer cells. In this trial, PPM will be instilled into the bladder cavity to treat bladder cancer that does not invade into the muscle layer of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2024
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts
Conditions: Non-muscle-invasive Bladder Cancer
TRUDI: TDXD+Durva in HER2+/low IBC
Recruiting
The purpose of this study is to test the safety and effectiveness of an investigational drug combination (trastuzumab deruxtecan and durvalumab) to learn whether the intervention works in treating Human Epidermal growth factor Receptor-2 (HER2)-expressing inflammatory breast cancer.
The names of the study drugs involved in this study are:
* Trastuzumab deruxtecan
* Durvalumab
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
Recruiting
This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in patients with HER2-positive advanced solid tumors with or without brain metastases.
The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Dana-Farber Cancer Insitute, Boston, Massachusetts
Conditions: Advanced Solid Tumors, HER2-positive Breast Cancer
Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Recruiting
This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer.
The names of the study drugs involved in this study are:
* Axatilimab (a type of antibody)
* Olaparib (a type of PARP inhibitor)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
Recruiting
A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: University of Massachusetts Chan Medical School, Worcester, Massachusetts
Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer